Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
A pharma industry veteran with over three decades of experience in domestic as well as international markets
91% of cloud leaders expect their cloud capabilities to be largely centralized within the next 2 years and 64% of cloud leaders have realized cybersecurity cost savings by migrating to cloud
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Subscribe To Our Newsletter & Stay Updated